Clearmind says Japan publishes patent application on 3-MMC-based dyskinesia treatment
PUBT · 1d ago
Share
Listen to the news
- Clearmind Medicine published a Japanese patent application covering 3-MMC-based methods and compositions to prevent or treat dyskinesia.
- Claims also cover combining 3-MMC with palmitoylethanolamide, targeting an added anti-inflammatory or neuroprotective effect.
- The filing expands the company’s intellectual property footprint for its 3-MMC program in neurological movement disorders.
- Work ties to Clearmind’s collaboration with NeuroThera Labs, which contributes palmitoylethanolamide technology to its therapeutic platform.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080732PRIMZONEFULLFEED9842147) on October 08, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending